Programmed death-ligand 1 expression in rectal cancer

被引:0
作者
G. Jomrich
G. R. Silberhumer
B. Marian
A. Beer
L. Müllauer
机构
[1] Medical University of Vienna,Department of Surgery
[2] Medical University Vienna,Institute of Cancer Research
[3] Medical University Vienna,Clinical Institute of Pathology
来源
European Surgery | 2016年 / 48卷
关键词
Rectal cancer; Programmed death ligand 1; Tumor-infiltrating lymphocytes; Neoadjuvant chemoradiation; Total mesorectal excision;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:352 / 356
页数:4
相关论文
共 154 条
[1]  
Ferlay J(2015)Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012 Int J Cancer 136 E359-E386
[2]  
Soerjomataram I(2004)Preoperative versus postoperative chemoradiotherapy for rectal cancer N Engl J Med 351 1731-1740
[3]  
Dikshit R(2013)Impact of KRAS, BRAF and PI3KCA mutations in rectal carcinomas treated with neoadjuvant radiochemotherapy and surgery BMC Cancer 13 200-17
[4]  
Eser S(2015)Current state of anti-PD-L1 and anti-PD-1 agents in cancer therapy Mol Immunol 67 4-979
[5]  
Mathers C(2009)Overexpression of PD-L1 significantly associates with tumor aggressiveness and postoperative recurrence in human hepatocellular carcinoma Clin Cancer Res 15 971-2028
[6]  
Rebelo M(2015)Pembrolizumab for the treatment of non-small-cell lung cancer N Engl J Med 372 2018-2454
[7]  
Sauer R(2012)Safety, activity, and immune correlates of anti-PD-1 antibody in cancer N Engl J Med 366 2443-800
[8]  
Becker H(2002)Tumor-associated B7-H1 promotes T‑cell apoptosis: a potential mechanism of immune evasion Nat Med 8 793-1034
[9]  
Hohenberger W(2000)Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation J Exp Med 192 1027-264
[10]  
Rodel C(2012)The blockade of immune checkpoints in cancer immunotherapy Nat Rev Cancer 12 252-325